MANITOBA
Submission of Patient Evidence

As a new service to patients and caregivers, the Canadian Patient Coalition is now assisting patients and caregivers in submitting their opinions and concerns to various government agencies.

The government of Manitoba is currently reviewing Colesevelam (Lodalis) for public listing.

As part of the decision-making process, the governments consider input from patients who provide feedback to a registered patient organization in the province.

The Canadian Patient Coalition is seeking patient input to incorporate into a submission and is seeking interested patients who can provide perspective on how Colesevelam (Lodalis) has impacted their health and helped them to manage hypercholesterolemia.

Patients interested in sharing their experience are requested to go to the links provided to fill out a survey that will prompt them to describe their experience taking Colesevelam (Lodalis).

The Canadian Patient Coalition would appreciate receiving messages from interested patients by the end of the day on Thursday, February 28, 2026.

Patients will be asked provide their name, email address and postal code (to ensure the patient resides in the province of record). Patient names and other identifying information are not disclosed as part of the patient submission process - this information remains anonymous.

Please complete the following form. All 5 sections must be completed.

Section I - Author Information
Patient names and personal information are not disclosed as part of the Manitoba patient submission process - this information remains anonymous. Nevertheless we need this information (name, email address and postal code) to ensure the patient resides in Manitoba)
Date:
Drug & Indication:
Who Are You:Patient   Care Giver
Name:
Address:
City:
Province:
Postal Code:
Phone:
Email:
Section II - Impact of the Disease/Condition
What symptoms and problems do patients have as a result of the disease/condition?
How does the condition affect day-to-day life?
For example, are there activities that patients are not able to do as a result of the condition?
Section III - Treatment outcomes that matter most to Patients
What are the most important aspects of the condition that patients would like to see addressed by treatments?
In terms of treatment efficacy and side effects, what are patients getting from the existing treatments and what would patients like new treatments to do differently?
Are there other practical implications to be considered in determining the value of a treatment? For example, how do treatments impact patients' or caregivers' daily routine or lifestyle?
In addition to the drug cost, are there other financial implications to patients or caregivers (e.g. traveling cost, time away from work, drug disposal issues, drug administration supplies)?
Section IV - Information from Patients who have used this drug
For patients who have used this drug as part of a clinical trial or from a manufacturer's compassionate supply or have purchased it through other means (private insurance or paid out of pocket).
What positive and negative impacts does the drug have on the condition?
Which symptoms is the drug best or worst at treating (advantages and disadvantages)?
What difference does the drug make to patients' long-term health and wellbeing?
What are the side effects of the drug, which ones are patients prepared to put up with, and which ones do they find unacceptable?
How does the drug compared with other available treatments in terms of efficacy, side effects and other practical implications (e.g. administration, time, costs)?
Section V - Confirmation of Authorship
I declare that I am the sole author of this submission and confirm that no other parties had input into the submission.
        Date: